Country eligibility info - Horizon Europe

Belgium - Member States
Please note that this information sheet will be updated regularly and the list of countries divided into the different categories can always change over the period of Horizon Europe. If you are involving a partner from a non-EU country in your consortium please always check the status of this country in Horizon Europe at the moment of submission in the Horizon Europe Programme Guide.

Belgium belongs to the group of Member States

Funding possible - Scroll further to find out what this means exactly

Specific remarks for Belgium

No extra info available

Eligibility for Member States means...

Short explanation

Legal entities in Member States can participate and receive funding in all parts of Horizon Europe. However in some call topics, limitations or conditions may also be attached to those entities which are controlled directly or indirectly by entities from ineligible countries (Third Country) [Article 22.5 of the Horizon Europe Regulation].

In general legal entities in Member States can coordinate projects in all calls with the exception of calls under the widening and spreading excellence part of Horizon Europe. In these calls only the so called widening countries and outermost regions of Member States can coordinate projects.

N/A

All details regarding country eligibility is compiled in the infosheet “International cooperation".

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.